Masq-Aute: Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Completed
CT.gov ID
NCT04427176
Collaborator
(none)
15
1
29
15.7

Study Details

Study Description

Brief Summary

The current outbreak of Covid-19 requires the wearing of FFP2 respiratory protective devices by healthcare personnel to limit their contamination.

However, there is currently a shortage of masks in France due to insufficient national stocks while the disease is spreading.

There is an urgent need to save FFP2 masks to enable healthcare personnel to continue to provide care in complete safety. Contamination of staff due to insufficient masks would have consequences by limiting access to care for infected patients and putting caregivers at potential risk of death. Caregiver protection is also intended to contain the risk of nosocomial epidemics. We propose the use of ARFC masks by Covid-19+ units. These ARFC masks provide optimal security against the risk of aerosolization of contaminated biological liquids. They are masks modified to be usable by civilians, resulting from the technology of combat masks, specially designed for use in NRBC (Nuclear, Radiological, Biological and Chemical) atmosphere.

Condition or Disease Intervention/Treatment Phase
  • Device: ARFC mask

Study Design

Study Type:
Observational
Actual Enrollment :
15 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Evaluation of ARFC Masks Equipped With CF5 Filter in the Care Unit to Allow a Wider Distribution of FFP2 Masks (Covid-19).
Actual Study Start Date :
Apr 29, 2020
Actual Primary Completion Date :
May 28, 2020
Actual Study Completion Date :
May 28, 2020

Arms and Interventions

Arm Intervention/Treatment
Nurses

Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne will be included. They will be wear ARFC mask.

Device: ARFC mask
Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.

Outcome Measures

Primary Outcome Measures

  1. Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of tolerance [Hour: 48]

    Tolerance will be assessed by the nursing staff by means of a visual analogue scale from 0: no tolerance to 10: perfect tolerance. It will be evaluated 48 hours after the inclusion.

  2. Evaluate the feasibility of the use of an ARFC mask by nursing staff, in terms of compatibility with technical gestures. [Hour: 48]

    Compatibility will be assessed by the number of catheter insertion and blood sampling failures in relation to the total number of catheter insertions and blood sampling indicated at 48 hours after the inclusion.

Secondary Outcome Measures

  1. Assess the acceptability of the wearing of an ARFC mask by nursing staff [Hours: 0, 48]

    To compare acceptability questionnaires complete at inclusion and 48 jours after.

  2. To assess the minor complications of wearing the ARFC mask . [Hour: 48]

    Occurrence of minor complications related to the wearing of the mask as reported for non-invasive ventilation (dry mouth, nose, conjunctivitis, skin lesions at the support point, etc.).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Nursing staff working 8 or 12 hours a day for 2 consecutive days in a COVID unit at the hospital of Saint Etienne.

  • Subjects affiliated to or entitled to a social security scheme

  • Subject who received informed information about the study and agreed to participate in the study

Exclusion Criteria:
  • Allergy to ARCF mask material: polyurethane

  • Impossibility of supporting a tight mask on the face

  • Potential contraindication to wearing a mask, such as the existence of claustrophobia

  • Beard and moustache wearer

  • Suspicion of COVID-19 infection

  • Refusal to participate.

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Saint-Etienne Saint-Étienne France

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: Jean-Luc PERROT, MD PhD, CHU SAINT-ETIENNE

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT04427176
Other Study ID Numbers:
  • 20CH073
  • 2020-A00817-32
First Posted:
Jun 11, 2020
Last Update Posted:
Jun 29, 2020
Last Verified:
Jun 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 29, 2020